Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia

Experimental Cell Research

Volumn 316, Issue 3, 2010, Pages 466-476

  Law, Alice Y S ^a   Wong, Chris K C ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

ChIP assay; HDAC7; p300; Promoter analysis; X box binding protein

Indexed keywords

CYCLIN D; HISTONE DEACETYLASE 7; HYPOCALCIN; HYPOXIA INDUCIBLE FACTOR 1; PROTEIN P300; STANNIOCALCIN 2; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; GENE ACTIVATION; GENE DELETION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GROWTH REGULATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; SITE DIRECTED MUTAGENESIS; SOLID TUMOR; UPREGULATION;

EID: 72149117661     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.09.018     Document Type: Article

References (37)

1. Chang A.C., and Reddel R.R. Identification of a second stanniocalcin cDNA in mouse and human: stanniocalcin 2. Mol. Cell. Endocrinol. 141 (1998) 95-99
2. DiMattia G.E., Varghese R., and Wagner G.F. Molecular cloning and characterization of stanniocalcin-related protein. Mol. Cell. Endocrinol. 146 (1998) 137-140
3. Ishibashi K., Miyamoto K., Taketani Y., Morita K., Takeda E., Sasaki S., and Imai M. Molecular cloning of a second human stanniocalcin homologue (STC2). Biochem. Biophys. Res. Commun. 250 (1998) 252-258
4. Moore E.E., Kuestner R.E., Conklin D.C., Whitmore T.E., Downey W., Buddle M.M., Adams R.L., Bell L.A., Thompson D.L., Wolf A., Chen L., Stamm M.R., Grant F.J., Lok S., Ren H., and De Jongh K.S. Stanniocalcin 2: characterization of the protein and its localization to human pancreatic alpha cells. Horm. Metab. Res. 31 (1999) 406-414
5. Chang A.C., Jellinek D.A., and Reddel R.R. Mammalian stanniocalcins and cancer. Endocr. Relat. Cancer. 10 (2003) 359-373
6. Bouras T., Southey M.C., Chang A.C., Reddel R.R., Willhite D., Glynne R., Henderson M.A., Armes J.E., and Venter D.J. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res. 62 (2002) 1289-1295
7. Charpentier A.H., Bednarek A.K., Daniel R.L., Hawkins K.A., Laflin K.J., Gaddis S., MacLeod M.C., and Aldaz C.M. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res. 60 (2000) 5977-5983
8. Buckanovich R.J., Sasaroli D., O'Brien-Jenkins A., Botbyl J., Hammond R., Katsaros D., Sandaltzopoulos R., Liotta L.A., Gimotty P.A., and Coukos G. Tumor vascular proteins as biomarkers in ovarian cancer. J. Clin. Oncol. 25 (2007) 852-861
9. Esseghir S., Kennedy A., Seedhar P., Nerurkar A., Poulsom R., Reis-Filho J.S., and Isacke C.M. Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin. Cancer Res. 13 (2007) 3164-3173
10. Iwao K., Matoba R., Ueno N., Ando A., Miyoshi Y., Matsubara K., Noguchi S., and Kato K. Molecular classification of primary breast tumors possessing distinct prognostic properties. Hum. Mol. Genet. 11 (2002) 199-206
11. McBryan J., Howlin J., Kenny P.A., Shioda T., and Martin F. ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene 26 (2007) 6406-6419
12. McCudden C.R., Majewski A., Chakrabarti S., and Wagner G.F. Co-localization of stanniocalcin-1 ligand and receptor in human breast carcinomas. Mol. Cell. Endocrinol. 213 (2004) 167-172
13. Meyer H.A., Tolle A., Jung M., Fritzsche F.R., Haendler B., Kristiansen I., Gaspert A., Johannsen M., Jung K., and Kristiansen G. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur. Urol. 55 (2009) 669-678
14. Koumenis C. ER stress, hypoxia tolerance and tumor progression. Curr. Mol. Med. 6 (2006) 55-69
15. Koumenis C., and Wouters B.G. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol. Cancer Res. 4 (2006) 423-436
16. Koumenis C., Naczki C., Koritzinsky M., Rastani S., Diehl A., Sonenberg N., Koromilas A., and Wouters B.G. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol. Cell. Biol. 22 (2002) 7405-7416
17. Law A.Y., Lai K.P., Ip C.K., Wong A.S., Wagner G.F., and Wong C.K. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp. Cell Res. 314 (2008) 1823-1830
18. Leonard M.O., Cottell D.C., Godson C., Brady H.R., and Taylor C.T. The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. J. Biol. Chem. 278 (2003) 40296-40304
19. Ito D., Walker J.R., Thompson C.S., Moroz I., Lin W., Veselits M.L., Hakim A.M., Fienberg A.A., and Thinakaran G. Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol. Cell. Biol. 24 (2004) 9456-9469
20. Mole D.R., Blancher C., Copley R.R., Pollard P.J., Gleadle J.M., Ragoussis J., and Ratcliffe P.J. Genome-wide association of hypoxia-inducible factor (HIF)-1{alpha} and HIF-2{alpha} DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 284 (2009) 16767-16775
21. Yeung H.Y., Lai K.P., Chan H.Y., Mak N.K., Wagner G.F., and Wong C.K. Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology 146 (2005) 4951-4960
22. Law A.Y., Lai K.P., Lui W.C., Wan H.T., and Wong C.K. Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation. Exp. Cell Res. 314 (2008) 2975-2984
23. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., and Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
24. Wenger R.H., Stiehl D.P., and Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci. STKE 2005 (2005) 1-13
25. Kasper L.H., Boussouar F., Boyd K., Xu W., Biesen M., Rehg J., Baudino T.A., Cleveland J.L., and Brindle P.K. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J. 24 (2005) 3846-3858
26. Kasper L.H., and Brindle P.K. Mammalian gene expression program resiliency: the roles of multiple coactivator mechanisms in hypoxia-responsive transcription. Cell Cycle 5 (2006) 142-146
27. Chang A.C., Hook J., Lemckert F.A., McDonald M.M., Nguyen M.A., Hardeman E.C., Little D.G., Gunning P.W., and Reddel R.R. The murine stanniocalcin 2 gene is a negative regulator of post-natal growth. Endocrinology 149 (2008) 2403-2410
28. Gagliardi A.D., Kuo E.Y., Raulic S., Wagner G.F., and DiMattia G.E. Human stanniocalcin-2 exhibits potent growth-suppressive properties in transgenic mice independently of growth hormone and IGFs. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E92-105
29. Raulic S., Ramos-Valdes Y., and DiMattia G.E. Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro. J. Endocrinol. 197 (2008) 517-529
30. Tamura K., Furihata M., Chung S.Y., Uemura M., Yoshioka H., Iiyama T., Ashida S., Nasu Y., Fujioka T., Shuin T., Nakamura Y., and Nakagawa H. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci. 100 (2009) 914-919
31. Romero-Ramirez L., Cao H., Nelson D., Hammond E., Lee A.H., Yoshida H., Mori K., Glimcher L.H., Denko N.C., Giaccia A.J., Le Q.T., and Koong A.C. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 64 (2004) 5943-5947
32. Acosta-Alvear D., Zhou Y., Blais A., Tsikitis M., Lents N.H., Arias C., Lennon C.J., Kluger Y., and Dynlacht B.D. XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol. Cell 27 (2007) 53-66
33. Kimura H., Weisz A., Ogura T., Hitomi Y., Kurashima Y., Hashimoto K., D'Acquisto F., Makuuchi M., and Esumi H. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J. Biol. Chem. 276 (2001) 2292-2298
34. Ieta K., Tanaka F., Yokobori T., Kita Y., Haraguchi N., Mimori K., Kato H., Asao T., Inoue H., Kuwano H., and Mori M. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int. J. Cancer 125 (2009) 926-931
35. Joensuu K., Heikkila P., and Andersson L.C. Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett. 265 (2008) 76-83
36. Anderson A.R., Weaver A.M., Cummings P.T., and Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127 (2006) 905-915
37. Yoshida H. Unconventional splicing of XBP-1 mRNA in the unfolded protein response. Antioxid. Redox Signal. 9 (2007) 2323-2333